UNSPSC 51434008: Pentolonium tartrate

This classification denotes a nicotinic antagonist and antihypertensive agent with the molecular formula C15H32N2.2C4H5O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953357GACY, chemically known as 1,1-pentamethylenebis(1-methylpyrrolidinium tartrate) but more generally known as pentolinium tartrate, which bears US NIH Compound Identifier 5849. European Medicines Agency schedules Pentolonium tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09700MIG.

The term PENTOLINIUM TARTRATE is an International Non-Proprietary Name. Most nations, for tariff and trade purposes, schedule pentolonium tartrate under HS 29339990. SMILES: C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.

UNSPSC 51434008 Pentolonium tartrate is a Commodity code that captures pharmaceutical raw materials and finished medications procured by state and local emergency services, public health agencies, and state pharmacy benefit programs. Recent solicitations show state and local governments buying Advanced Life Support medications, generic multi-source pharmaceuticals, and over-the-counter products through competitive sealed bids, cooperative purchasing agreements, and exploratory RFIs. The work spans direct medication supply to municipal fire departments, statewide pharmacy benefit program procurement through cooperative alliances, and state-level pharmacy infrastructure modernization. Issuing bodies include municipal purchasing departments (City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing organizations (MMCAP administered by Minnesota Department of Administration). All recent activity requires vendors to comply with FDA requirements, cGMP standards, DSCSA certification, OSHA Hazard Communication Standards, and federal accessibility requirements where applicable.

Geographic spread concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP). The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications—including 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem—with electronic bids due April 8, 2026, and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting capacity outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026, awarded vendors to begin service July 1, 2026, and pricing weighted at 75 percent of evaluation criteria.